Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
isavuconazole (Cresemba®)
Reference No. 2433
Publication date:
04/01/2017
Appraisal information
isavuconazole (Cresemba®) 100 mg capsule
isavuconazole (Cresemba®) 200 mg powder for concentrate for solution for infusion
Company:
Basilea Pharmaceuticals Ltd
BNF category:
Infections
NMG meeting date:
02/11/2016
AWMSG meeting date:
07/12/2016
Submission Type:
Full Submission
Status:
Recommended
Advice No:
3616
Ratification by Welsh Government:
22/12/2016
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
Isavuconazole (Cresemba®) is recommended as an option for use within NHS Wales for the treatment of invasive aspergillosis in adults and the treatment of mucormycosis in adult patients for whom amphotericin B is inappropriate. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
Final Appraisal Recommendation (FAR)
Download
isavuconazole (Cresemba) 2433 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
isavuconazole (Cresemba) 2433 ASAR
Clinical Expert (CE) Summary
Download
isavuconazole (Cresemba) 2433 CE summary
